Myelodysplastic syndromes (MDSs) consist of a family of hematopoietic stem cell (HSC) disorders characterized by ineffective differentiation of hematopoietic progenitors, bone marrow dysplasia, genetic instability and a propensity to develop acute myeloid leukemia. The development of MDS is poorly understood and therefore, effective treatment options are limited. Recent progress has been made in identifying altered signaling pathways and understanding the HSC defects, which are thought to contribute to the pathogenesis of MDS. Several of these findings have implicated aberrant expression and function of microRNAs (miRNAs). Unique miRNA expression patterns have been identified in MDS patients and modeled in mice to recapitulate features of MDS. Here, we review miRNA expression profiles identified in MDS patients, and describe the association of miRNA expression with MDS subtypes and disease outcome, clinical implications of miRNAs in MDS and deregulation of miRNAs in mouse model systems of MDS.
Introduction

Myelodysplastic syndrome (MDS)
MDS are clonal hematopoietic stem cell (HSC) disorders in which genetic and/or epigenetic alterations compromise the function of hematopoietic stem and progenitors cells (HSPCs) and contribute to blood cytopenias and marrow cell dysplasia. 1 Many MDS patients will also progress to acute myeloid leukemia (AML) on acquisition of additional mutations in the defective HSPC compartment. 2 Accurate diagnosis, prognosis and treatment of MDS is hindered because of the heterogeneity and complexity of the disease. The most current classification of MDS, according to the World Health Organization, now comprises eight subtypes based on biological, genetic and morphological features. 3 These include refractory anemia (RA), RA with ringed sideroblasts, RA with multilineage dysplasia (RCMD), RA with multilineage dysplasia and ringed sideroblasts (RCMD-RS), RA with excess blasts-1, RA with excess blasts-2, MDS unclassified and MDS associated with isolated deletion chromosome 5q (del(5q)) (also known as 5q-syndrome). A separate category now encompasses the myelodysplastic/ myeloproliferative neoplasms, which include chronic myelomonocytic leukemia, polythemia vera, essential thrombocythemia and myelofibrosis. Risk assessment and prognosis, as defined by the International Prognostic Scoring System, has been divided into four risk categories: low-risk, intermediate-1 risk, intermediate-2 risk and high-risk.
Regardless of subtype or risk category, MDS is thought to arise from a CD34
þ HSC that has acquired genetic and/or epigenetic abnormalities. 4, 5 Thus, the CD34 þ cells are likely the more relevant population as compared with total bone marrow (BM) cells when investigating the underlying HSC defect in MDS. The prevailing model of MDS indicates that acquired mutations in CD34 þ cells result in the clonal advantage of a defective HSC that is incapable of supporting normal blood production. 6, 7 Insufficient knowledge about the basic biology of MDS remains an impediment to effective treatment strategies. Recent and encouraging advances, including the discovery of deregulated microRNA (miRNA) in MDS, have improved our understanding and provided novel clinical targets for MDS. microRNA miRNAs are 18 to 25 nucleotide non-coding RNAs highly conserved from invertebrates to vertebrates. 8 miRNAs are encoded as precursor hairpin intermediate RNAs and subsequently processed by endonuclease-mediated steps to yield the functional mature miRNA. 8 These steps involve the transcribed miRNA to be processed by Drosha (RNase endonuclease) in the nucleus to a hairpin precursor. On export to the cytoplasm, this miRNA precursor is further processed by Dicer (RNase endonuclease) resulting in a mature miRNA, which is then incorporated into the RNA interfering silencing complex. 8 Repression of protein translation and RNA decay are the bestdescribed functions of miRNAs, which are achieved by imperfect hybridization to the target messenger RNAs (mRNA) 3 0 untranslated regions (UTR). 9 Although not as common, miRNAs are also reported to enhance post-transcriptional protein expression of target mRNAs, 10 and control transcription by directly regulating DNA methylation. 11 At the time of this review, there are 1424 annotated human miRNAs in miRBase (release 17) . This list will likely expand in conjunction with the declining cost of high-throughput sequencing, and because of increasing enthusiasm for the field.
Various miRNA identification and detection methods have emerged; the most popular include northern blotting, microarrays, reverse transcriptase-PCR and more recently next generation RNA sequencing. [12] [13] [14] Of these methods, only microarrays and RNA sequencing allow for global highthroughput miRNA detection. These methods differ in that microarrays rely on annotated miRNAs while RNA sequencing will identify all known and novel miRNAs. 12 As northern blot analysis and reverse transcriptase-PCR utilize hybridizationbased detection, these methods require prior knowledge (that is, nucleotide sequence) about the specific miRNA of interest. 12 As expected, each approach has benefits and disadvantages, and SPOTLIGHT therefore inconsistencies and variation are found among the different miRNA expression studies.
Overview of miRNAs in regulating hematopoiesis
Hematopoiesis is a tightly regulated process that maintains efficient and rapid mature blood production while preserving the HSC pool. The importance of miRNAs as key regulators of hematopoiesis and HSC function is evident. The most comprehensive analysis implicating miRNAs in hematopoiesis showed that certain miRNAs are distinctly expressed in mouse hematopoietic sub-populations. 15 This finding is supported by Dicerdeficient mice, which are unable to process any mature miRNA. The Dicer-deficient mice are depleted of HSC, 16 exhibit developmental defects in pro-B cells, 17 as well as impaired T-cell differentiation and cytokine production. 18 Extensive reviews are available that summarize the relevant miRNAs in mouse HSC and their putative mRNA targets. 19, 20 As MDS originates in the HSC population, this review will briefly elaborate on key miRNAs found in normal human HSC subsets. Unlike mouse HSC, the human HSC phenotype is less well defined and, in particular, adult HSC are difficult to obtain in sufficient amounts for high-throughput RNA sequencing analyses. Therefore, all published reports on human CD34 þ cells describe the relative miRNA abundance by microarray or reverse transcriptase-PCR, techniques that permit analysis of smaller quantities of RNA. In one study, BM and immobilized blood CD34 þ cells were used to estimate the abundance of miRNAs based on fluorescent intensity of microarray probes. 21 The reported miRNAs abundantly expressed in CD34 þ cells include, but not limited to, let-7b, miR-10a, miR-25, miR-26 family, miR-128a, miR-146, miR-155, miR-181a, miR-222 and miR-223. A second study examined the relative differences in miRNA expression between CD34 þ CD38 À and CD34 þ CD38 þ cells. It was shown that miR-127, miR-365, miR-452 and miR-520h were highly expressed in the more primitive CD34 þ CD38 À HSC population. 22 The miR-125 family has also been implicated in HSC function. Ooi et al.
identified higher expression of miR-125b in lin-
. Differences in miRNA expression between umbilical cord and adult BM CD34 þ cells were also investigated. 24 Thirteen miRNAs were differentially expressed between umbilical cord and BM CD34 þ cells: miR-548d, miR-203, miR-1, miR-34a, miR-545, let-7b, miR-429, miR-214, miR-195, miR-520h, miR-518a, miR-519d and miR-517c.
miRNAs in blood-related cancers
Inspection of human genomes revealed that approximately half of all miRNA genes are located at fragile sites and regions of copy-number alteration associated with cancer. 25 Gene expression profiling of human cancers confirmed that miRNAs are significantly deregulated, and miRNA expression signatures can reproducibly classify and distinguish human cancers. 26 Consistent with these findings, 70% of miRNAs are located within copy-number alterations in AML and MDS cell lines; however, only 20% of the miRNAs are expressed at levels above background. 27 These findings suggest that one mechanism of miRNA deregulation in oncogenesis is due to genomic instability. Given the significance of miRNA regulation of hematopoiesis, it is not surprising that expression of miRNAs is also perturbed in hematological malignancies. The earliest evidence of altered miRNA expression because of a cytogenetic alteration comes from work in chronic lymphocytic leukemia. Two miRNAs, miR-15a and miR-16, were identified as tumor suppressors at 13q14, a region commonly deleted in chronic lymphocytic leukemia, by targeting BCL2. 28, 29 Numerous profiling and functional experiments have since implicated deregulation of miRNAs in other human hematological malignancies. miRNA expression signatures from normal CD34 þ and AML cells revealed several key miRNAs. 30 For example, miR-155, miR-196b, miR-25, miR-101, miR-146a, miR-223, miR-29 and miR-125a are implicated in the pathobiology of AML. 30, 31 Others have correlated miRNA expression changes with leukemia subtype, cytogenetic profile and molecular alterations. 30, [32] [33] [34] 
miRNAs in MDSs
Evidence of abnormal miRNA expression in MDS High-throughput miRNA analysis. While substantial progress in understanding the role of miRNAs in human AML has been achieved, unfortunately, by comparison, much less is known about the role of miRNAs in MDS. The best evidence that implicates miRNAs in the pathogenesis of MDS comes from hypothesis-driven analyses, rather than from global gene expression profiling experiments. Notwithstanding, several recent papers and conference proceedings have described aberrant expression of miRNAs in MDS patients using microarray-based platforms (Table 1) .
In the first publication, 35 miRNAs were collected from unsorted BM cells from 24 MDS patients and three control samples and applied to a low-density real-time PCR-based array. The cohort consisted of approximately 60% low-risk and 40% high-risk patients (Table 1) . Interestingly, the miRNA signature distinguished MDS entities with chromosomal alterations from ones with a normal karyotype (Tables 2 and 3 ). For instance, RA/ RCMD with a normal karyotype expressed six unique miRNAs as compared with RA/RCMD with trisomy 8, all of which are downregulated in trisomy 8 as compared with normal karyotype RA/RCMD. MDS patients with del(5q) also exhibited a distinct miRNA profile relative to RA/RCMD with a normal karyotype (Tables 2 and 3) .
Utilizing a similar approach, Sokol et al. 36 examined global miRNA expression in BM mononuclear cells isolated from 44 MDS patients and 17 normal controls. The cohort included 66% low-risk/intermediate-1 and 33% intermediated-2/high-risk MDS patients (Table 1) . Of 290 miRNAs detected by the microarray, 76 were differentially expressed between all MDS patients and controls (42 upregulated/34 downregulated). Of these, the expression of 13 miRNAs was significantly different between MDS and controls (Tables 2 and 3 ). The discriminatory potential of differentially expressed miRNAs was also examined between low-and high-risk MDS patients. The investigators reported that high expression of miR-181a/c/d, miR-221, miR-376, miR-125b, miR-155, miR-130a and low expression of miR-486-5p were associated with high-risk MDS patients and accurately differentiated from low-risk patients.
Also using mononuclear BM cells, Erdogan et al. 37 examined miRNA expression by Agilent miRNA arrays from 10 MDS patients and 10 normal marrows. The patient cohort consisted primarily of lower-risk patients, as only three developed AML within 2 years. For validation, RNA was also collected from formalin-fixed paraffin-embedded clot sections. Expression profiles were consistent between RNA isolated from BM SPOTLIGHT mononuclear cell suspensions and the corresponding formalinfixed paraffin-embedded clot section, suggesting that various sources of patient material are amenable to miRNA profiling for diagnostic and prognostic purposes. In conclusion, 13 miRNAs were differentially expressed between MDS and normal samples (Tables 2 and 3) , of which miR-150, miR-342 and miR-103 have been implicated in hematopoiesis.
In a fourth study, miRNAs were isolated from CD34 þ BM cells from 43 MDS patients and 9 healthy donors. 38 As the CD34 þ population is strongly implicated as containing the abnormal HSC in MDS, the information drawn from such studies may yield more knowledge about intrinsic HSC defects. The patient cohort consisted of 40% low-risk and 60% high-risk disease, some of which also included AML ( Table 1) . As compared with normal controls, 22 miRNAs were differentially expressed across all the MDS subtypes using an Illumina array platform (human v2, Illumina Inc., San Diego, CA, USA). Of which, 13 miRNA were upregulated and 9 were downregulated (Tables 2 and 3 ). Hierarchical clustering of 22 differentially expressed miRNAs resulting in five distinct clusters distinguished normal from MDS patients, and also the MDS subtypes.
MDS with an isolated del(5q) (5q-syndrome) is considered a distinct subtype, and is characterized by macrocytic anemia, mild neutropenia and thrombocytosis associated with hypolobulated megakaryocytes. miRNA expression profiles were assayed in CD34 þ BM cells from seven 5q-syndrome patients and five controls using high-density TaqMan arrays. 39 Of 365 probes, 21 miRNAs differed between 5q-syndrome patients and Abbreviations: All MDS, indicates that the expression of the miRNA was not distinguished between different MDS subtypes within the particular study; CMML, chronic myelomonocytic leukemia; del(5q), deletion of chromosome 5q; MDS, myelodysplastic syndrome; miRNA, microRNA; RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; RCMD, refractory anemia with multilineage dysplasia; tri8, trisomy chromosome 8. controls (Tables 2 and 3 ). These included 17 overexpressed miRNAs and 4 underexpressed miRNAs. Of these, the expression of miR-34a is most significantly affected in 5q-syndrome patients. An in depth analysis was performed of miRNAs that map within or near the commonly deleted regions on del(5q).
SPOTLIGHT
Only miR-146a was significantly reduced in CD34 þ cells isolated from 5q-syndrome patients, yet nonsignificant differences were observed for miR-143, miR-145 and miR-378 (Tables 2 and 3 ). However, miR-143 was downregulated and miR-146a was upregulated in peripheral blood granulocytes of 5q-patients. No differences in miRNA expression were observed in monocytes or T-lymphocytes.
Only one study has examined miRNA expression in patients with myelodysplastic/myeloproliferative neoplasms. 40 This study examined a select group of myelopoiesis-associated miRNAs from the BM of chronic myelomonocytic leukemia patients by PCR. Surprisingly only differential expression of miR-10a (downregulated) was reported in chronic myelomonocytic leukemia (but not chronic myeloid leukemia) relative to controls and atypical chronic myeloid leukemia. It was concluded by the investigators that despite different composition of the marrows between the different myeloproliferative neoplasms subtype, the relative expression of myelopoiesisassociated miRNAs remained constant. Another interpretation Table 3 Overexpressed miRNAs in MDS Abbreviations: All MDS, indicates that the expression of the miRNA was not distinguished between different MDS subtypes within the particular study; CMML, chronic myelomonocytic leukemia; del(5q), deletion of chromosome 5q; MDS, myelodysplastic syndrome; miRNA, microRNA; RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; RCMD, refractory anemia with multilineage dysplasia; tri8, trisomy chromosome 8.
is that deregulation of miRNAs may be most prominent in MDS and AML, but less in the myeloproliferative disorders.
Expression analysis of specific miRNAs. Several other reports have profiled select miRNAs in MDS patients. Pons et al. 41 determined the expression of 25 mature miRNAs from the BM of 25 MDS patients and 12 control marrows. The patient cohort included a majority of low-risk MDS patients (88%) with a normal karyotype (56%), which were predominately classified as RCMD and RCMD-RS. Of the 25 miRNAs examined by PCR, 12 miRNA were differentially expressed (Tables 2 and 3 ). These include overexpression of the miR-17-92 cluster, miR-10a/b, miR-15a/miR-16, miR-21, miR-126, miR-155, miR-181 and miR-222 between patients and controls, and differential expression of miR-15a and miR-16 between low-risk and high-risk patients. Consistent with AML studies mentioned above, increased expression of miR-10a, miR-155, miR-181a and miR-222 were observed in the MDS patients, suggesting that overlap in the micronome may exist between certain subsets of AML and MDS.
All annotated miRNAs residing with the del(5q) region in MDS patients were examined for abnormal expression patterns. 42 Of the 13 miRNAs, significantly reduced expression of miR-145 and miR-146a was observed in BM cells from del(5q) MDS patients as compared with controls and MDS patients diploid at chr 5q. 42 This expression pattern was also observed in CD34 þ cells. 42 Although three independent groups also reported that miR-145 and/or miR-146a are reduced in CD34 þ or whole marrow cells, 39, 43, 44 differences in expression of these miRNAs were not observed by Boultwood et al. 45 and Hussein et al.
35
Evaluation of miR-150 and miR-221/miR-222 was performed in 52 MDS patients with low-and high-risk groups. 46 Interestingly, miR-150 was significantly overexpressed in del(5q) MDS and with MDS patients with good cytogenetic risk profiles. In contrast, miR-221 did not significantly differ between controls and MDS patients in any cohort examined. The investigators went on to show that miR-150 expression inversely correlated with its target, MYB, in patient samples. That is, increased miR-150 expression correlated with lower MYB expression. Interestingly, c-Myb mutant mice exhibit thrombocytosis, 47 which may explain the elevated platelets in 5q-patients.
Upregulation of miR-125b by six-to ninefold was identified in MDS patients with t(2;11)(p21;q23). 48 Focus was placed on miR-125b as it is located near the breakpoint at chr 11 and is the only gene in this region with abnormal expression in MDS patients with the t(2;11) breakpoint. Ectopic expression of miR-125b in primary human CD34 þ cells interfered with differentiation of monocytes and granulocytes, suggesting that miR-125b is a key gene that is deregulated by the t(2;11) breakpoint in MDS. 48 The aforementioned studies have provided insight into the miRNA landscape of MDS patients and the potential contribution to cellular basis of MDS. As summarized in Figure 1 , abnormal expression of certain miRNAs (for example, miR-125 and miR-155) within the primitive BM compartment may promote aberrant HSC self-renewal and progression to AML. In addition, altered expression of miRNAs within mature MDS blood cells (for example, miR-145, miR-146, miR-150 and miR-222) may contribute to differentiation defects resulting in neutropenia, thrombocytopenia and/or anemia (Figure 1 ). Despite this progress and insight, very little overlap exists between deregulated miRNAs among the studies (Tables 2 and 3 , and Figure 1) . Therefore, future studies should implement larger patient cohorts and provide a consistent sample source in order to more effectively uncover deregulated miRNA expression signatures in MDS. Given the heterogeneity of MDS, miRNA expression will also need to be carefully analyzed according MDS subtypes, risk groups and in the appropriate cell population.
Mechanisms contributing to abnormal miRNA expression in MDS
Abnormal expression and alterations in function of miRNAs are undoubtedly evident and therefore may contribute to the pathophysiology of MDS. There is a wealth of information about mechanisms of miRNA deregulation in human cancer. Although there are fewer studies describing mechanisms of deregulated miRNAs in MDS, the underlying mechanisms are likely to be similar as reported in other human cancers types.
Unbalanced cytogenetic alterations are the most common structural abnormality in MDS patients. Over 50% of MDS patients exhibit large copy-number gains and losses. [49] [50] [51] Recently, it has been shown that many of the MDS patients with a purported normal karyotype also have cryptic genomic Figure 1 Overview of miRNA contribution to features of MDS. An overview of key cellular, clinical and morphological features of MDS (highlighted in red font to the left and right of the figure) as relating to HSC, hematopoietic progenitors, erythroid cells (Eryth), megakaryocytes (Mk), and white blood cells (WBCs). miRNAs that are reported to be overexpressed (up: within red box above the figure) and downregulated (down: within green box below the figure) are highlighted. Only miRNAs that were identified by more than one study from Tables 2 and 3 alterations when analyzed by high-resolution DNA arrays. [49] [50] [51] Therefore, cytogenetic alterations are likely a major contributor of altered miRNA expression. It is well established that genomic regions containing sequence alterations and fragile sites in solid tumors are enriched with miRNAs. 25 A recent detailed genomic analysis of MDS and AML samples and found that majority of miRNAs (B70%) map to copy-number alterations. 27 However, when the absolute expression level of the miRNAs was determined by massively parallel small RNA sequencing, only B20% of these miRNAs are expressed at or above notable levels. When compared with normal CD34 þ cells, a majority of these 'expressed' miRNAs (470%) significantly differed in expression in the AML and MDS samples. This study suggests that many miRNAs are located in fragile sites and regions of genomic alterations, and the expression of only a subset of these miRNAs is significantly altered and likely relevant in myeloid malignancies. As these studies were primarily performed in cell lines, a similar study is warranted in MDS patient samples to confirm these interpretations.
SPOTLIGHT
Most emphasis has been placed on miRNAs residing within or near the chr 5q deletion. As discussed above, only a subset of the 13 miRNAs on chr 5q are significantly reduced in expression as compared with controls or MDS patients with a diploid chr 5q. Although different technical approaches have been used to study the expression, there is some consensus as to the potentially relevant miRNAs that are impacted by the del(5q). Of note, miR-378, miR-143, miR-143*, miR-145 and miR-146a are reported by multiple groups to be reduced in MDS patients with del(5q). 27, 38, 39, 42, 44 Deletion of whole or part of chr 7 and gains of chr 8 are also common recurring abnormalities in MDS. 2 Despite a minimally deleted region mapped to an approximately 2-3 Mb segment at 7q22, 52, 53 not much is known about the genes or miRNAs on chr 7 and their role in MDS. Although not within the minimally deleted region on chr 7, deregulated expression of miR-148 and miR-182 has been associated with MDS. miR-182 (7q32.2) is reduced in MDS patient samples with del(5q) relative to RA/ RCMD. 35 Expression of miR-148 has not been reported in monosomy 7 MDS patients, but has been examined in other MDS subtypes. Two independent groups have reported significant overexpression of miR-148 in del(5q) MDS patients. 35, 39 Although balanced genomic alterations are rare in MDS, the translocation of chromosomes 2 and 11 has been reported. 48 The translocation, t(2;11)(p21;q23), did not result in a novel gene fusion, but rather contributed to the abnormal elevated expression of a single gene, miR-125b, located near the breakpoint. 48 Therefore, in rare cases with balanced genomic alterations, miRNA deregulation may be a contributing factor. Acquisition of somatic mutations or MDS-associated singlenucleotide polymorphisms within miRNAs is another mechanism by which miRNA function may be altered in MDS. Sequencing of miRNAs from an MDS cell line (and five additional AML cell lines) by massively parallel small RNA sequencing did not provide evidence that miRNAs acquire somatic mutations. 27 However, there was evidence of alternative miRNA species, such as miRNA sequence variants and miRNAs with post-transcriptional editing of nucleotides, which could significantly impact the miRNA binding to its target mRNA. 27 The functional consequences of miRNA editing and nucleotide additions/deletions need further investigation.
Alterations in epigenetic marks are common in human cancer. 54 Recently, somatic mutations in DNMT3A, which encodes a DNA methyltransferase, have been identified in de novo AML, 55 suggesting that abnormal methylation of the genome is associated with hematological malignancies. Similar mutations have not been reported in MDS patients yet; however, aberrant DNA hypermethylation is associated with poor prognosis, and demethylation inhibitors are used as a treatment option in MDS. 56, 57 In one reported example, miR-124, which is downregulated in MDS patients as compared with normal BM, 58 was evaluated for methylation defects in fifteen MDS patients (including RCMD, RA with excess blasts-1, RA with excess blasts-2 and chronic myelomonocytic leukemia). It was reported that miR-124 expression inversely correlated with the degree of promoter methylation. 58 In support of this finding, methylation and silencing of miR-124 by ecotropic virus integration site 1 contributes to HSC defects and MDS-like disease in mice. 59 
Clinical implications of deregulated miRNAs in MDS
Identification of specific miRNA biomarkers for MDS could improve diagnosis, prognosis and disease management. As in other human diseases, the potential of miRNAs as biomarkers and therapeutics has yet to be completely realized. Unlike protein coding genes, miRNAs have added benefits in the clinical setting. For example, miRNA expression profiles can successfully be used to classify differentiated cancers, while mRNA profiles did not discriminate when applied to the same sample set. 26 Additionally, miRNAs are more stable in degraded RNA preparations allowing for a more robust, feasible and reliable analysis. 60 A single miRNA has the ability to control a vast network of mRNA targets; therefore, the information from and potential of manipulating a few miRNA may have tremendous clinical benefit. 9 As described above, several miRNAs have been identified as being deregulated in MDS subtypes. Diagnosis and prognosis is particularly challenging in MDS patients with a normal karyotype, therefore, miRNAs as biomarkers may be an important tool in disease management. Knowledge gained from these studies should be an impetus to perform prospective studies and evaluate the true benefits as diagnostic and prognostic tools.
Selecting the appropriate source of RNA to evaluate miRNA expression in MDS is contentious. To understand the underlying molecular defects in MDS, selecting the most relevant HSC population is pertinent, but not necessary for diagnostic and prognostic measures. Overexpressed miRNAs will likely be the best candidate biomarkers to pursue. Blood plasma, microvessicles or BM cells may serve as potential sources of miRNA biomarkers for MDS, all of which have been validated as sources for other cancers. In support of this premise, circulating let-7a and miR-16 from plasma from MDS patients were recently shown to predict progression-free survival and overall survival. 61 Given the relative stability of miRNAs, retrospective analysis of miRNAs from paraffin-embedded sections is also possible as recently demonstrated for MDS. 62 Although the IPSS assigns prognostic scores to patients with MDS, hope remains that miRNA biomarkers will improve on the current approach.
Given that diagnosis and prognosis of MDS is most challenging for patients categorized as low risk, miRNA biomarkers in this cohort of MDS patients may be most beneficial. Preliminary findings show promise that miRNAs can be used for diagnostic purposes in MDS. 36, 38 In one study, hierarchical clustering performed for a set of 45 differentially expressed mRNAs resulted in five clusters, which distinguished low-risk from highrisk MDS. The expression of two miRNAs, miR-422a and miR-617 (in addition to HS_63 and HS_305), correlated with disease progression. Their expression was low in normal samples and low-risk MDS, yet high in advanced MDS and AML. In a second study, a 13 miRNA signature distinguished SPOTLIGHT miRNAs and MDSMDS patients from controls. 36 In addition, 10 distinct miRNAs discriminated between low-risk/intermediate-1 and intermediate-2/high-risk MDS patients. Overexpression of miR-181 in the highrisk cohort may indicate disease progression because elevated expression of miR-181 is also reported in AML. 34 Future studies should determine whether low-risk MDS patients with a normal karyotype could be distinguished from age-matched normal controls. To realize the benefits of miRNAs as biomarkers, substantial retrospective and prospective investigations are necessary to convincingly correlate miRNA expression profiles to outcome, prognosis and treatment response in MDS patients.
Lenalidomide is the most effective treatment for 5q-syndrome patients, often resulting in improved marrow morphology, complete cytogenetic remissions and red blood cell transfusion independence. 63 Low-risk MDS patients, other than ones with del(5q), are also showing promising response to Lenalidomide therapy. 64 Although the erythroid defect observed in 5q-syndrome is attributed to haploinsufficiency of RPS14, 44, 65, 66 the mechanism of Lenalidomide action does not likely involve RPS14. 67 In contrast, CDC25C and PP2A, two cell cycle genes located on chr 5q, have been shown to contribute to the Lenalidomide response. 68 In addition, miR-145 and miR-146a, miRNAs on chr 5q that are expressed low in 5q-syndrome patients, are elevated in expression following Lenalidomide treatment and are associated with erythroid responses and cytogenetic remission in a pre-clinical trial. 43 This observation is supportive of the finding that haploinsufficiency of miR-145 and miR-146a contributes to 5q-syndrome features in mice. 27, 42 As whole marrow cells were used to monitor miRNA expression in the pre-clinical study, it is not clear whether increased expression of miR-145 and miR-146a following treatment is due to re-expression from the intact arm of chr 5q in the diseased cells, or if miR-145 and miR-146a expression correlates with the emergence of normal cells in the marrow of treated patients. This issue has been partly addressed in another recent study. 69 In vitro Lenalidomide treatment of CD34 þ from patients with MDS resulted in induction of miR-143 and miR-145, but the same effect was not observed in CD34 À cells. Furthermore, Lenalidomide-mediated induction of miR-143 and miR-145 in vitro correlated with clinical response to Lenalidomide in patients, irrespective of del(5q) status. On the other hand, non-responders in the del(5q) group were unable to upregulate miR-145 following treatment with Lenalidomide. Collectively, these studies suggest a role for miRNAs as markers for drug response.
Administration of miRNA mimics or antagomiRs as therapeutic agents for MDS is a desirable goal for future treatment. In vivo delivery of naked DNA, oligonucleotides and miRNAs is complicated by their low stability, rapid degradation and inefficient delivery into target cells. 70 Research on liposome-based carriers for delivery of miRNA mimics or antagomiRs may provide a solution to the challenges of standard miRNA delivery approaches.
Mouse models of deregulated miRNAs and MDS
Dicer1 ablation
Evidence that global miRNA deregulation is involved in the pathogenesis of MDS comes from Dicer1 knockout mice. In this model, Dicer1, an RNasIII endonuclease essential for miRNA biogenesis, was specifically deleted in mouse osteoprogenitors, rather than in the hematopoietic stem/progenitor compartment. 71 Mice with deleted Dicer1 in the osteoprogenitors developed abnormal hematopoiesis, MDS and eventual AML mediated because of an altered hematopoietic/stromal niche.
Altered expression of Sbds, a gene mutated in ShwachmanBodian-Diamond syndrome, was reduced in the osteoprogenitors in the Dicer1-deleted mice. 71 Deletion of Sbds in mouse osteoprogenitors resulted in altered BM function and MDS-like features. Although this model does not implicate abnormal miRNA expression in the HSC compartment, it does strongly suggest that non-autonomous factors from the stroma and/or a compromised stromal environment contribute to MDS. Similar evidence is observed in studies wherein mesenchymal cells were isolated from MDS patients and karyotyping performed. 72 In these reports, the mesenchymal cells from the MDS patients exhibited cytogenetic alterations and were less efficient at supporting hematopoiesis of normal HSC cells.
Depletion of miR-145 and miR-146a
It is reported that several miRNA residing on chr 5q are reduced in MDS patients with del(5q), including miR-143, miR-145, miR-146a and miR-378, 39, [42] [43] [44] and their loss has been suggested to contribute to features of 5q-syndrome. Knockdown of miR-145 and miR-146a using a miRNA decoy approach in mouse HSPC resulted in thrombocytosis, mild neutropenia, megakaryocytic dysplasia and progression to a fatal myeloid malignancy in a subset of mice. 27, 42 Mal/TIRAP and Fli1 were identified as targets of miR-145, 42, 44 and TRAF6 was confirmed to be a target of miR-146a (Figure 2) . 42, 73, 74 Mal/TIRAP and TRAF6 are two proteins that lie in the MyD88-dependent pathway of innate immune signaling upstream of nuclear factor-kB. 75, 76 A murine BM transplant model in which TRAF6 is retrovirally overexpressed, similarly results in megakaryocytic and platelet defects through a paracrine effect (via interleukin-6), and a survival advantage resulting in AML or BM failure through a cell-intrinsic mechanism (Figure 2) . 42 The macrocytic anemia associated with 5q-syndrome was not evident in the mouse model with reduced miR-145 and miR-146a expression. These findings support the model in which the erythroid defect observed in 5q-syndrome is the result of haploinsufficiency of RPS14. 65, 66 Combined deletion of RPS14 and miR-145 in a mouse model has been investigated and is reported to recapitulate nearly the entire spectrum of clinical features of 5q-syndrome, including macrocytic anemia, thrombocytosis and megakaryocyte dysplasia (Figure 2) . 44 Additional insights into the role of miR-145 in 5q-syndrome will hopefully come from generation and analysis of miR-145 knockout mice.
miR-146a knockout
As miR-145 is implicated in dysmegakaryopoiesis in 5q-syndrome, what is the role of miR-146a? The potential SPOTLIGHT Figure 2 Model of deregulated miRNAs in 5q-syndrome. Deletion of chr 5q encompasses RPS14, miR-145 and miR-146a. Loss of RPS14 is associated with erythroid apoptosis and macrocytic anemia. Loss of miR-145 is associated with elevated platelets, in part by derepression of Mal/TIRAP and Fli1. Loss of miR-146a results in increased TRAF6 expression. Reduced miR-146a expression is thought to contribute to neutropenia, BM failure (BMF) and AML.
contribution of miR-146a to dysmegakaryopoiesis is not resolved. Transient knockdown of miR-146a in human CD34 þ cells resulted in increased megakaryocyte proliferation, differentiation and maturation in vitro.
77 Surprisingly, overexpression of miR-146a in mouse HSPC did not affect megakaryopoiesis or platelet formation in vivo. 74, 78 In these later studies, it is possible that overexpression of miR-146a beyond endogenous levels is not sufficient to have a biological effect on megakaryocytes. An alternative interpretation claims that non-autonomous factors contribute to megakaryopoiesis and elevated platelets following knockdown of endogenous miR-146a. This is supported by the finding that knockdown of miR-146a in mouse HSPC results in elevated interleukin-6, which is a positive regulator of megakaryopoiesis. 42 Knockout of the miR-146a locus has recently been described, and results in a complex immune and hematological phenotype. [79] [80] [81] Germline deletion of miR-146a results in myeloid expansion in the marrow, anemia, leukopenia, thrombocytopenia and marrow fibrosis. 79 Although the mice exhibit lower platelets and fewer BM megakaryocytes, evidence of increased megakaryopoiesis in the spleen of the knockout mice was observed. 81 With a long latency, miR-146a homozygous knockout mice succumb to a myeloid malignancy associated with expansion of immature myeloid blasts, BM failure and occasionally lymphomas. 79, 81 Increased nuclear factor-kB activation is thought to partly contribute to the defects as reduction in nuclear factor-kB levels rescues the myeloid defects in the miR-146a knockout mice. 79 The miR-146a knockout mice also exhibit increased STAT1, nuclear p65/RelA, TRAF6, IRAK1, interleukin-6, tumor necrosis factor-a and interleukin-1b expression. [79] [80] [81] Loss of miR-146a results in autoimmunity, likely due to abnormal Treg-mediated regulation of Th1 responses, and/or hyper-responsiveness to pathogens (for example, lipopolysaccharide). 80, 81 According to these findings, independent technical approaches suggest that reduced miR-146a expression contributes to features of MDS and leukemia.
miR-125 family overexpression
As described above, increased expression of miR-125b is observed in t(2;11)(p21;q23) and miR-125a in del(5q) MDS, and interferes with monocyte and granulocyte differentiation of primary human CD34 þ cells. 48 Interestingly, miR-125a and miR-125b, which are part of the miR-125 family and have identical seed regions, are enriched in HSCs compared with other BM cells, and confer a competitive advantage to engrafting human hematopoietic cells in mice. 82 Overexpression of miR-125b in mouse HSPCs also resulted in a survival advantage of immature HSC, a dose-dependent myeloproliferative disorder and eventual progression to a fatal myeloid leukemia in mice, possibly due to suppression of BM failure and KLF13 mRNA targets. 16, 23, 82 Future experiments should validate whether the suppressed mRNA targets are responsible for the manifestation of the HSC advantage and myeloid disease phenotype in mice. Nevertheless, in vivo evidence supports a role of miR-125b in the pathogenesis of dyshematopoiesis and MDS.
Conclusions and future considerations
The main obstacle to understanding and effectively treating MDS is insufficient knowledge of the biology of the disease. Although miRNAs have emerged as critical regulators of hematopoiesis and their aberrant expression has been associated with various types of leukemia, only recent findings have implicated deregulation of miRNAs in MDS patients and key factors in the pathogenesis of MDS. Initial findings suggest a potential of miRNAs as tools for diagnosis, prognosis and therapeutic response of MDS patients. miRNA expression profiling and mouse experiments have implicated select miRNAs in MDS (Tables 2 and 3 ). These findings have identified some miRNAs with overlapping functions in acute leukemia and HSC biology, but others that are unique to MDS.
A single miRNA has many (for example, hundreds) predicted mRNA targets. Whether aberrant expression of a miRNA in MDS correspondingly results in deregulation of a signal relevant mRNA target or multiple targets is not known. Evidence suggests that miRNAs function as rheostats; 83 therefore, it is compelling to speculate that aberrant expression of a miRNA will have a greater impact if it coordinates the expression of multiple genes within a signaling pathway, rather than altering the expression of just a single mRNA target. Alternatively, both scenarios could be true and may be necessary for an altered miRNA to contribute to MDS. Additional mouse models will provide necessary insight into the biology and function of deregulated candidate miRNAs and their potential contribution to MDS. MDS is a heterogeneous hematological disease with few treatment options. Increased knowledge about the role of miRNAs in MDS and their potential as clinical tools may improve the current management of MDS.
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